News articles about Heska (NASDAQ:HSKA) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Heska earned a news impact score of 0.17 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.2231127120914 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Heska (HSKA) traded up $1.93 on Wednesday, reaching $80.41. 52,900 shares of the company’s stock were exchanged, compared to its average volume of 52,420. The stock has a market capitalization of $568.49, a PE ratio of 42.10, a price-to-earnings-growth ratio of 2.07 and a beta of 0.74. Heska has a 52-week low of $75.21 and a 52-week high of $115.00.
Heska (NASDAQ:HSKA) last released its earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.03. The firm had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. Heska had a net margin of 10.67% and a return on equity of 15.35%. The company’s quarterly revenue was down 6.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.45 earnings per share. equities research analysts predict that Heska will post 2.03 earnings per share for the current fiscal year.
In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the business’s stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the transaction, the insider now directly owns 106,771 shares in the company, valued at $9,304,024.94. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 14.70% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This news story was published by Week Herald and is the property of of Week Herald. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://weekherald.com/2018/01/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-heska-hska-stock-price.html.
Heska Company Profile
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.